|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IARS |
Gene summary for IARS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IARS | Gene ID | 3376 |
| Gene name | isoleucyl-tRNA synthetase 1 | |
| Gene Alias | GRIDHH | |
| Cytomap | 9q22.31 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | P41252 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3376 | IARS | CCI_1 | Human | Cervix | CC | 2.31e-12 | 5.29e-01 | 0.528 |
| 3376 | IARS | CCI_2 | Human | Cervix | CC | 2.27e-22 | 1.01e+00 | 0.5249 |
| 3376 | IARS | CCI_3 | Human | Cervix | CC | 1.09e-21 | 6.82e-01 | 0.516 |
| 3376 | IARS | CCII_1 | Human | Cervix | CC | 9.25e-04 | 1.62e-01 | 0.3249 |
| 3376 | IARS | Tumor | Human | Cervix | CC | 8.49e-22 | 3.48e-01 | 0.1241 |
| 3376 | IARS | sample3 | Human | Cervix | CC | 1.78e-27 | 4.05e-01 | 0.1387 |
| 3376 | IARS | H2 | Human | Cervix | HSIL_HPV | 4.00e-05 | 1.67e-01 | 0.0632 |
| 3376 | IARS | T1 | Human | Cervix | CC | 2.20e-03 | 1.24e-01 | 0.0918 |
| 3376 | IARS | T2 | Human | Cervix | CC | 8.72e-04 | 1.78e-01 | 0.0709 |
| 3376 | IARS | T3 | Human | Cervix | CC | 7.90e-34 | 4.62e-01 | 0.1389 |
| 3376 | IARS | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.12e-20 | -5.02e-01 | 0.0155 |
| 3376 | IARS | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.15e-11 | -5.02e-01 | -0.1808 |
| 3376 | IARS | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.20e-08 | -5.02e-01 | -0.0811 |
| 3376 | IARS | HTA11_78_2000001011 | Human | Colorectum | AD | 6.98e-14 | -5.02e-01 | -0.1088 |
| 3376 | IARS | HTA11_347_2000001011 | Human | Colorectum | AD | 8.95e-22 | -5.02e-01 | -0.1954 |
| 3376 | IARS | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.14e-09 | -5.02e-01 | -0.1207 |
| 3376 | IARS | HTA11_83_2000001011 | Human | Colorectum | SER | 5.03e-07 | -5.02e-01 | -0.1526 |
| 3376 | IARS | HTA11_696_2000001011 | Human | Colorectum | AD | 3.49e-32 | -5.02e-01 | -0.1464 |
| 3376 | IARS | HTA11_866_2000001011 | Human | Colorectum | AD | 2.12e-29 | -5.02e-01 | -0.1001 |
| 3376 | IARS | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.93e-16 | -5.02e-01 | -0.059 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:01400531 | Liver | HCC | mitochondrial gene expression | 82/7958 | 108/18723 | 1.49e-12 | 7.20e-11 | 82 |
| GO:00325431 | Liver | HCC | mitochondrial translation | 62/7958 | 76/18723 | 2.95e-12 | 1.34e-10 | 62 |
| GO:00065202 | Liver | HCC | cellular amino acid metabolic process | 167/7958 | 284/18723 | 1.91e-08 | 4.56e-07 | 167 |
| GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:01400533 | Oral cavity | OSCC | mitochondrial gene expression | 78/7305 | 108/18723 | 2.37e-12 | 9.86e-11 | 78 |
| GO:00325434 | Oral cavity | OSCC | mitochondrial translation | 59/7305 | 76/18723 | 7.21e-12 | 2.70e-10 | 59 |
| GO:00063991 | Oral cavity | OSCC | tRNA metabolic process | 101/7305 | 179/18723 | 1.65e-06 | 2.15e-05 | 101 |
| GO:003466011 | Oral cavity | LP | ncRNA metabolic process | 205/4623 | 485/18723 | 6.46e-18 | 1.09e-15 | 205 |
| GO:003254313 | Oral cavity | LP | mitochondrial translation | 43/4623 | 76/18723 | 2.85e-09 | 1.26e-07 | 43 |
| GO:014005312 | Oral cavity | LP | mitochondrial gene expression | 53/4623 | 108/18723 | 3.54e-08 | 1.27e-06 | 53 |
| GO:00325433 | Prostate | BPH | mitochondrial translation | 23/3107 | 76/18723 | 2.21e-03 | 1.22e-02 | 23 |
| GO:01400532 | Prostate | BPH | mitochondrial gene expression | 29/3107 | 108/18723 | 4.68e-03 | 2.25e-02 | 29 |
| GO:003254312 | Prostate | Tumor | mitochondrial translation | 24/3246 | 76/18723 | 1.73e-03 | 1.03e-02 | 24 |
| GO:014005311 | Prostate | Tumor | mitochondrial gene expression | 31/3246 | 108/18723 | 2.31e-03 | 1.30e-02 | 31 |
| GO:003466013 | Skin | cSCC | ncRNA metabolic process | 234/4864 | 485/18723 | 1.37e-26 | 4.77e-24 | 234 |
| GO:00325436 | Skin | cSCC | mitochondrial translation | 47/4864 | 76/18723 | 4.70e-11 | 2.22e-09 | 47 |
| GO:01400535 | Skin | cSCC | mitochondrial gene expression | 56/4864 | 108/18723 | 8.06e-09 | 2.56e-07 | 56 |
| GO:00063993 | Skin | cSCC | tRNA metabolic process | 64/4864 | 179/18723 | 2.34e-03 | 1.36e-02 | 64 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IARS | SNV | Missense_Mutation | c.712G>A | p.Val238Ile | p.V238I | P41252 | protein_coding | deleterious(0.02) | probably_damaging(0.919) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| IARS | SNV | Missense_Mutation | c.1143N>C | p.Leu381Phe | p.L381F | P41252 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| IARS | SNV | Missense_Mutation | c.2864C>G | p.Thr955Arg | p.T955R | P41252 | protein_coding | tolerated(0.44) | benign(0) | TCGA-AO-A03P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | PD | |
| IARS | SNV | Missense_Mutation | c.3661N>G | p.Arg1221Gly | p.R1221G | P41252 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.721) | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| IARS | SNV | Missense_Mutation | rs367830465 | c.2423N>A | p.Arg808His | p.R808H | P41252 | protein_coding | tolerated(0.14) | benign(0) | TCGA-BH-A18N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IARS | SNV | Missense_Mutation | c.3282A>T | p.Gln1094His | p.Q1094H | P41252 | protein_coding | tolerated(0.11) | benign(0.001) | TCGA-C8-A132-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| IARS | SNV | Missense_Mutation | novel | c.2329A>G | p.Thr777Ala | p.T777A | P41252 | protein_coding | tolerated(0.13) | benign(0.196) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| IARS | insertion | Nonsense_Mutation | novel | c.3345_3346insTGCTGCAAATTTTTGTGATTTCCTGTCTCCATATTCCAGAATTTAT | p.Ser1116CysfsTer6 | p.S1116Cfs*6 | P41252 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| IARS | insertion | Nonsense_Mutation | novel | c.782_783insTATCAAATAAT | p.Arg262IlefsTer3 | p.R262Ifs*3 | P41252 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| IARS | insertion | Frame_Shift_Ins | novel | c.3184_3185insT | p.Gly1062ValfsTer3 | p.G1062Vfs*3 | P41252 | protein_coding | TCGA-B6-A0IM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |